Reclast Gets FDA Kidney Failure Warning

posted on Sep 01 by MedPage Today OB/Gyn in the Uncategorized category (MedPage Today) -- The osteoporosis drug zoledronic acid (Reclast) should not be used in patients with significant renal impairment, and physicians should screen patients for kidney dysfunction before starting them on the drug, the FDA said.